# Covis Pharma GmBH, Waltham, MA – FDA Inspections

Source: https://www.keypedia.com/companies/covis-pharma-gmbh/d1616a5d-a379-4021-b5aa-ef8f369c9a92

> Inspection records and compliance data for Covis Pharma GmBH in Waltham, Massachusetts. 8 FDA inspections on record, last inspected September 19, 2024.

---

## Details

- Name: Covis Pharma GmBH
- FEI Number: 3008152278
- Address Line 1: 1100 Winter St
- City: Waltham
- State: Massachusetts
- Zip Code: 02451
- Country Name: United States
- Address: 1100 Winter St, Waltham, Massachusetts 02451, United States
- Country: United States

## Related Documents

- FDA Inspection 1250807 - Covis Pharma GmBH - 2024-09-19 — source: FDA, date: September 19, 2024
- [FDA Inspection 1250807 - Covis Pharma GmBH - 2024-09-19](https://www.keypedia.com/records/fda_inspections/covis-pharma-gmbh/9d7b8cb0-e107-4ecb-bc9d-dba336151f37) — classification: No Action Indicated (NAI), source: FDA, date: September 19, 2024
- [EIR - Covis Pharma GmBH - 2019-04-05](https://www.keypedia.com/records/eir/covis-pharma-gmbh/96266907-6479-4062-9364-c049059438c8) — source: FDA, date: April 5, 2019
- FDA Inspection 1087302 - Covis Pharma GmBH - 2019-04-05 — classification: No Action Indicated (NAI), source: FDA, date: April 5, 2019
- [EIR - Covis Pharma GmBH - 2018-10-22](https://www.keypedia.com/records/eir/covis-pharma-gmbh/e1c3ac92-6d3d-4fd5-b444-b1dc9d39cbf4) — source: FDA, date: October 22, 2018
- FDA Inspection 1071326 - Covis Pharma GmBH - 2018-10-22 — classification: No Action Indicated (NAI), source: FDA, date: October 22, 2018
- [FDA Inspection 981007 - Covis Pharma GmBH - 2016-07-15](https://www.keypedia.com/records/fda_inspections/covis-pharma-gmbh/e03436c5-2531-4b26-94ec-738dabe9dd52) — classification: Voluntary Action Indicated (VAI), source: FDA, date: July 15, 2016
- [FDA Inspection 892953 - Covis Pharma GmBH - 2014-07-28](https://www.keypedia.com/records/fda_inspections/covis-pharma-gmbh/88fb2b99-8685-4234-b6dc-1010f35b4c7d) — classification: No Action Indicated (NAI), source: FDA, date: July 28, 2014
- [EIR - Covis Pharma GmBH - 2014-05-21](https://www.keypedia.com/records/eir/covis-pharma-gmbh/ca25746d-042f-44fb-9023-feac3e8caca7) — source: FDA, date: May 21, 2014
- [483 - Covis Pharma GmBH - 2014-05-21](https://www.keypedia.com/records/483/covis-pharma-gmbh/d31460cb-08fd-45a3-ab4d-1dbc66de56ec) — source: FDA, date: May 21, 2014
- FDA Inspection 878312 - Covis Pharma GmBH - 2014-05-21 — classification: Voluntary Action Indicated (VAI), source: FDA, date: May 21, 2014
- FDA Inspection 878312 - Covis Pharma GmBH - 2014-05-21 — classification: No Action Indicated (NAI), source: FDA, date: May 21, 2014
- [EIR - Covis Pharma GmBH - 2013-02-07](https://www.keypedia.com/records/eir/covis-pharma-gmbh/517ef4b2-926e-4c85-b0dc-313096252028) — source: FDA, date: February 7, 2013
- [483 - Covis Pharma GmBH - 2013-02-07](https://www.keypedia.com/records/483/covis-pharma-gmbh/63a7c09e-9210-463a-8653-f60b4b6c0244) — source: FDA, date: February 7, 2013
- FDA Inspection 819091 - Covis Pharma GmBH - 2013-02-07 — classification: Voluntary Action Indicated (VAI), source: FDA, date: February 7, 2013
- FDA Inspection 819091 - Covis Pharma GmBH - 2013-02-07 — classification: No Action Indicated (NAI), source: FDA, date: February 7, 2013
- [EIR - Covis Pharma GmBH - 2011-08-03](https://www.keypedia.com/records/eir/covis-pharma-gmbh/4da4aee9-e25c-41b5-90be-9cb639c836ff) — source: FDA, date: August 3, 2011
- [483 - Covis Pharma GmBH - 2011-08-03](https://www.keypedia.com/records/483/covis-pharma-gmbh/55b430c0-50f3-46db-9e52-cf8160c30b8d) — source: FDA, date: August 3, 2011

## Related Companies

- [First Time US Generics LLC](https://www.keypedia.com/companies/first-time-us-generics-llc/f6359b6c-cd28-4749-a4da-8187845004bf)
- [Vemulkonda Koneti Rao, M.D.](https://www.keypedia.com/companies/vemulkonda-koneti-rao-md/1077f51d-4271-4061-bde8-34e77e0e820a)
- [OurPharma LLC](https://www.keypedia.com/companies/ourpharma-llc/2172e4a8-770c-45d9-9eb6-0321c8ba396f)
- [BRI Institutional Review Board, Inc.](https://www.keypedia.com/companies/bri-institutional-review-board-inc/27f73a19-9417-4b75-90db-3cd132eddbb1)
- [Axsome Therapeutics, Inc.](https://www.keypedia.com/companies/axsome-therapeutics-inc/0bc3d1e2-dfe0-47ba-b144-4248f1fdfdf0)
- [Keith A. Aqua, M.D.](https://www.keypedia.com/companies/keith-a-aqua-md/1b09891f-72da-4ee0-b524-946275c5044f)
- [Paramesh Banerji Life Sciences, LLC](https://www.keypedia.com/companies/paramesh-banerji-life-sciences-llc/8a5dcf24-e253-4116-a968-f9b1a890d15b)
- [Daniel Norman, M.D.](https://www.keypedia.com/companies/daniel-norman-md/bd34bdd0-4f58-4a86-9a6d-0cfc983e300c)
- [Charles River Laboratories, LLC](https://www.keypedia.com/companies/charles-river-laboratories-llc/596ec0f9-2c59-4d36-bdf1-bdee2009dd1f)
- [Innovative Intrathecal Solutions, Inc. dba Innovative Compounding Pharmacy](https://www.keypedia.com/companies/innovative-intrathecal-solutions-inc-dba-innovative-compounding-pharmacy/facccdb0-f578-40dc-b0e7-5a7ace70b3a0)

## Related Officers

- [company_representative](https://www.keypedia.com/people/lee-f-allen/08fcb582-4468-4954-9d76-faafde2086a2)
- [issuing_officer](https://www.keypedia.com/people/bei-yu/4d50b882-2813-4eb5-8bc5-f7045c7681ed)
- [Strategic Expert at NovoNordisk; Retired from FDA](https://www.keypedia.com/people/debra-m-emerson/58bd7fac-28eb-4369-b149-13a24cc00cf7)
- [investigator](https://www.keypedia.com/people/stacey-s-degarmo/f0dea08e-f65f-4664-9614-66f1997a95dc)
- [CSO at FDA](https://www.keypedia.com/people/justine-m-corson/5f6e4477-f060-47f1-9165-a63fd6a36226)